retatrutide approval status The Dosage Chart The FDA has issued warning

In many cases, patients who reach their target weight are transitioned to a maintenance phase

On Day 11, peripheral organs (heart, spleen, kidney, pancreas, liver, mesenteric, perirenal and epididymal white adipose tissue, interscapular brown adipose tissue) were collected and their wet organ weights measured

That connection matters for patients

doi: 10.1093/ajhp/62.2.173 86 GkeRFehmannHCLinnTSchmidtHKrauseMEngJet al

Potential risks include: Low blood sugar, especially if you also take other diabetes medications Gallbladder issues Mild to severe allergic reactions, including anaphylaxis in rare cases Possible muscle loss, if you lose weight too quickly (which is why balanced nutrition and movement matter) If youre pregnant or nursing, you should not take GLP-1s